Cargando…

Radiomics in Triple Negative Breast Cancer: New Horizons in an Aggressive Subtype of the Disease

In the last decade, the analysis of the medical images has evolved significantly, applications and tools capable to extract quantitative characteristics of the images beyond the discrimination capacity of the investigator’s eye being developed. The applications of this new research field, called rad...

Descripción completa

Detalles Bibliográficos
Autores principales: Mireștean, Camil Ciprian, Volovăț, Constantin, Iancu, Roxana Irina, Iancu, Dragoș Petru Teodor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836903/
https://www.ncbi.nlm.nih.gov/pubmed/35160069
http://dx.doi.org/10.3390/jcm11030616
_version_ 1784649792194871296
author Mireștean, Camil Ciprian
Volovăț, Constantin
Iancu, Roxana Irina
Iancu, Dragoș Petru Teodor
author_facet Mireștean, Camil Ciprian
Volovăț, Constantin
Iancu, Roxana Irina
Iancu, Dragoș Petru Teodor
author_sort Mireștean, Camil Ciprian
collection PubMed
description In the last decade, the analysis of the medical images has evolved significantly, applications and tools capable to extract quantitative characteristics of the images beyond the discrimination capacity of the investigator’s eye being developed. The applications of this new research field, called radiomics, presented an exponential growth with direct implications in the diagnosis and prediction of response to therapy. Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype with a severe prognosis, despite the aggressive multimodal treatments applied according to the guidelines. Radiomics has already proven the ability to differentiate TNBC from fibroadenoma. Radiomics features extracted from digital mammography may also distinguish between TNBC and non-TNBC. Recent research has identified three distinct subtypes of TNBC using IRM breast images voxel-level radiomics features (size/shape related features, texture features, sharpness). The correlation of these TNBC subtypes with the clinical response to neoadjuvant therapy may lead to the identification of biomarkers in order to guide the clinical decision. Furthermore, the variation of some radiomics features in the neoadjuvant settings provides a tool for the rapid evaluation of treatment efficacy. The association of radiomics features with already identified biomarkers can generate complex predictive and prognostic models. Standardization of image acquisition and also of radiomics feature extraction is required to validate this method in clinical practice.
format Online
Article
Text
id pubmed-8836903
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88369032022-02-12 Radiomics in Triple Negative Breast Cancer: New Horizons in an Aggressive Subtype of the Disease Mireștean, Camil Ciprian Volovăț, Constantin Iancu, Roxana Irina Iancu, Dragoș Petru Teodor J Clin Med Review In the last decade, the analysis of the medical images has evolved significantly, applications and tools capable to extract quantitative characteristics of the images beyond the discrimination capacity of the investigator’s eye being developed. The applications of this new research field, called radiomics, presented an exponential growth with direct implications in the diagnosis and prediction of response to therapy. Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype with a severe prognosis, despite the aggressive multimodal treatments applied according to the guidelines. Radiomics has already proven the ability to differentiate TNBC from fibroadenoma. Radiomics features extracted from digital mammography may also distinguish between TNBC and non-TNBC. Recent research has identified three distinct subtypes of TNBC using IRM breast images voxel-level radiomics features (size/shape related features, texture features, sharpness). The correlation of these TNBC subtypes with the clinical response to neoadjuvant therapy may lead to the identification of biomarkers in order to guide the clinical decision. Furthermore, the variation of some radiomics features in the neoadjuvant settings provides a tool for the rapid evaluation of treatment efficacy. The association of radiomics features with already identified biomarkers can generate complex predictive and prognostic models. Standardization of image acquisition and also of radiomics feature extraction is required to validate this method in clinical practice. MDPI 2022-01-26 /pmc/articles/PMC8836903/ /pubmed/35160069 http://dx.doi.org/10.3390/jcm11030616 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Mireștean, Camil Ciprian
Volovăț, Constantin
Iancu, Roxana Irina
Iancu, Dragoș Petru Teodor
Radiomics in Triple Negative Breast Cancer: New Horizons in an Aggressive Subtype of the Disease
title Radiomics in Triple Negative Breast Cancer: New Horizons in an Aggressive Subtype of the Disease
title_full Radiomics in Triple Negative Breast Cancer: New Horizons in an Aggressive Subtype of the Disease
title_fullStr Radiomics in Triple Negative Breast Cancer: New Horizons in an Aggressive Subtype of the Disease
title_full_unstemmed Radiomics in Triple Negative Breast Cancer: New Horizons in an Aggressive Subtype of the Disease
title_short Radiomics in Triple Negative Breast Cancer: New Horizons in an Aggressive Subtype of the Disease
title_sort radiomics in triple negative breast cancer: new horizons in an aggressive subtype of the disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836903/
https://www.ncbi.nlm.nih.gov/pubmed/35160069
http://dx.doi.org/10.3390/jcm11030616
work_keys_str_mv AT miresteancamilciprian radiomicsintriplenegativebreastcancernewhorizonsinanaggressivesubtypeofthedisease
AT volovatconstantin radiomicsintriplenegativebreastcancernewhorizonsinanaggressivesubtypeofthedisease
AT iancuroxanairina radiomicsintriplenegativebreastcancernewhorizonsinanaggressivesubtypeofthedisease
AT iancudragospetruteodor radiomicsintriplenegativebreastcancernewhorizonsinanaggressivesubtypeofthedisease